Clinical trial

Combined Use of Buzzy and EMLA Cream for Vascular Access in Children. A Randomized Controlled Trial

Name
RC 12/2019
Description
Venepuncture and peripheral intravenous cannulation are commonly performed in children and may cause substantial pain and distress. The aim of this study is to evaluate the efficacy of the combination of EMLA cream and Buzzy device in pain and distress relief during venipuncture or peripheral vascular access in hospitalized children. The study is an open randomized controlled study. Eligible children will be randomized to receive the application of EMLA cream 60 minutes before the needle procedure or the application of EMLA 60 minutes before the procedure and the use of Buzzy device during procedure. The primary study outcome will be the mean distress score experienced by children at the moment of the procedure, evaluated with the CEMS scale. Secondary outcomes will be the mean distress score recorded by operators; the self-reported mean pain score; the mean pain score reported by parents and operators.
Trial arms
Trial start
2023-04-01
Estimated PCD
2023-12-01
Trial end
2023-12-01
Status
Completed
Treatment
Buzzy device plus EMLA cream
EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
Arms:
Buzzy and EMLA Cream
Only EMLA cream
EMLA cream will be applied 60 minutes before the needle procedure
Arms:
EMLA Cream
Size
94
Primary endpoint
Mean distress evaluated by parents
Intraprocedural
Eligibility criteria
Inclusion Criteria: * children between 4 and 12yrs of age needing venipuncture or peripheral vascular access * children who have applied EMLA cream at least 60 minutes before the procedure Exclusion Criteria: * children with cognitive impairment * children with skin lesion that does not allow the application of Buzzy device * children diseases that cause hypersensibility to cold (i.e. Raynaud syndrome, sickle cell disease) * children who have taken any analgesics in the 8 hours before enrollment
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 94, 'type': 'ACTUAL'}}
Updated at
2024-03-19

1 organization

1 product

1 indication

Product
EMLA
Indication
Vascular Access